Crescendo Biologics
Latest round
- Series B
Last raised
- Apr 2018
Total raised
- $95M
Investors
- 11
About Crescendo Biologics
Founded in 2007 and headquartered in Cambridge, UK, Crescendo Biologics Limited specializes in biopharmaceutical development.Crescendo Biologics specializes in the development of innovative T cell-enhancing therapeutics aimed at addressing unmet medical needs in the field of immuno-oncology. Their core product offerings include the Humabody® platform, which features a range of bispecific and multivalent antibodies designed to engage T cells and target specific tumor cells effectively. Notable products in development include CB307, a bispecific T cell engager currently in clinical trials for patients with metastatic castration-resistant prostate cancer (mCRPC), and ZL-1102 (Humabody®, CB001), a topical treatment for psoriasis being evaluated in a global Phase 2 clinical trial.30 in 2023, with an EBITDA of USD -27,185,349. The company generates revenue through partnerships and collaborations with pharmaceutical companies and research institutions, enabling the development and commercialization of its proprietary products. Transactions typically involve licensing agreements and milestone payments contingent upon the successful progression of clinical trials for their flagship products, including Humabody® and Multibody® therapeutics. These agreements allow Crescendo Biologics to monetize its technologies while leveraging the expertise and resources of established partners to bring treatments to market. The company is targeting expansion into additional markets across Europe and Asia-Pacific by the end of 2024, aiming to broaden access to its therapeutics while enhancing its clinical trial capabilities.
Who invested in Crescendo Biologics
11 investors across 4 rounds
See all investors in Crescendo Biologics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Crescendo Biologics
Who invested in Crescendo Biologics?
Crescendo Biologics has 11 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Crescendo Biologics raised?
Crescendo Biologics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Crescendo Biologics last raise money?
Crescendo Biologics's most recent round on record is a Series B, in Apr 2018.
What does Crescendo Biologics do?
Founded in 2007 and headquartered in Cambridge, UK, Crescendo Biologics Limited specializes in biopharmaceutical development.
Where is Crescendo Biologics headquartered?
Crescendo Biologics is headquartered in Cambridge, UK.
Which VCs invest in companies like Crescendo Biologics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Crescendo Biologics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Crescendo Biologics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.